Skip to main
COGT

COGT Stock Forecast & Price Target

COGT Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 36%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Cogent Biosciences Inc. is positioned favorably due to positive clinical trial results for its drug bezuclastinib, which demonstrated significant benefits in both symptom reduction and survival rates compared to existing treatments, indicating strong therapeutic potential in the market. The company's robust financial foundation supports ongoing commercialization efforts and pipeline expansion, particularly in addressing unmet needs for patients with Systemic Mastocytosis and advanced gastrointestinal stromal tumors. Additionally, the anticipated approvals for bezuclastinib align with the growing demand for targeted therapies, underlining the company's prospective revenue generation capabilities.

Bears say

Cogent Biosciences faces significant risks due to potential negative clinical results from its CGT9486 program, which could lead to downward adjustments in market penetration, increased discount rates, and elongated timelines for regulatory approval. Concerns such as slower development, setbacks in trials, and the possibility of enhanced competitor products further jeopardize its valuation. Additionally, the company may experience long-term dilution risks and lower than projected commercial success, creating a challenging environment for maintaining investor confidence.

COGT has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 36% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cogent Biosciences, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cogent Biosciences, Inc. (COGT) Forecast

Analysts have given COGT a Buy based on their latest research and market trends.

According to 11 analysts, COGT has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cogent Biosciences, Inc. (COGT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.